Clinical Trials Browser

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT05038657 2022-10-03

AURORA

Phase 2 Unknown

36 enrolled

Genitourinary

Carcinoma, Squamous Cell, Urologic Neoplasms

NCT05396937 2022-05-31

Efficacy and Safety of T+A+RAD in HCC

Phase 2 Unknown

42 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03262454 2022-04-06

Atezolizumab

Phase 2 Unknown

35 enrolled

Thoracic

Small Cell Lung Cancer Recurrent

NCT03835949 2022-04-01

Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

Phase 1 Unknown

36 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05034055 2021-09-05

SKYROCKET

Phase 2 Unknown

45 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04739202 2021-03-29

IMMUNOGAST

Phase 2 Unknown

60 enrolled

Gastrointestinal

Adenocarcinoma, Stomach Neoplasms

NCT04696939 2021-01-06

Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients

Phase 2 Unknown

100 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03371992 2020-03-27

NO3DEXPL

Phase EARLY_PHASE1 Unknown

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03647956 2019-04-17

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Phase 2 Unknown

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03620435 2018-08-13

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

Phase 2 Unknown

25 enrolled

Safety Issues

NCT03616691 2018-08-06

Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC

Phase 2 Unknown

46 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

BladderGATE

MPDL3280A-treatment-IST-UMCG

A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

BELLA

Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation

Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

IMMUNOs-SBRT

ROME

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

SIRTCI

MARIO-3

BEACON

HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

MiST

Immunological Variables Associated to ICI Toxicity in Cancer Patients

AURORA

Efficacy and Safety of T+A+RAD in HCC

Atezolizumab

Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer

SKYROCKET

IMMUNOGAST

Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

NO3DEXPL

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC